186. EPMO Open Source Coordination Office Redaction File Detail Report

Produced by Araxis Merge on 7/9/2017 11:01:33 PM Eastern Daylight Time. See www.araxis.com for information about Merge. This report uses XHTML and CSS2, and is best viewed with a modern standards-compliant browser. For optimum results when printing this report, use landscape orientation and enable printing of background images and colours in your browser.

186.1 Files compared

# Location File Last Modified
1 PPS_N_3.0_Iter2_Build_360.zip\Unredacted\PS_PPS_srv\etc\csv\test ProductCSV_LargeExportTest.csv Fri Jun 30 19:04:12 2017 UTC
2 PPS_N_3.0_Iter2_Build_360.zip\Unredacted\PS_PPS_srv\etc\csv\test ProductCSV_LargeExportTest.csv Fri Jul 7 20:03:02 2017 UTC

186.2 Comparison summary

Description Between
Files 1 and 2
Text Blocks Lines
Unchanged 3 6
Changed 4 40
Inserted 0 0
Removed 0 0

186.3 Comparison options

Whitespace
Character case Differences in character case are significant
Line endings Differences in line endings (CR and LF characters) are ignored
CR/LF characters Not shown in the comparison detail

186.4 Active regular expressions

No regular expressions were active.

186.5 Comparison detail

  1   VaProductN ame^OiName ^PropInact ivationDat e^SynonymM ultiple^Wi tnessRequi red^Patien tSpecificL abel^Prote ctFromLigh t^DoNotHan dlePregnan t^FollowUp Time^Hazar dToDispose ^HazardToH andle^Haza rdToPatien t^LongTerm OutOfStock ^LowSafety Margin^Non Renewable^ LabMonitor MarkFormul ary^NcpdpD ispenseUni t^NcpdpQty Multiplier ^ApprovedF orSplittin g^DoNotMai l^ArWsAmis Category^A rWsAmisCon vertNumber ^DawCode^D ayOrDoseLi mit^DispDa ysSupplyLi mit^DispLi mitForOrde r^DispLimi tForSchedu le^DispOve rride^Disp OverrideRe ason^DispQ tyLimitDos e^DispQtyL imitTime^D ispQtyOver ride^DispQ tyOverride Reason^Dis pUnitPerOr derUnit^Fs nNsn^HighR iskMed^Hig hRiskFollo wup^HighRi skFollowup Time^Inpat MedExpOrdM axTime^Inp atMedExpOr dMinTime^M axDispense Limit^MaxD osePerDay^ RxMessage^ MonitorMax Days^Order Unit^DispO verrideRea sonBy^QtyD ispMessage ^RequestRe jectReason ^RejectRea sonText^Se condaryVaD rugClass^T otalDispen seQty^Unit DoseSchedu le^UnitDos eScheduleT ype^Refrig eration^De faultMailS ervice^Rec allLevel^T allmanLett ering^DeaS chedule^Mo nitorRouti ne^NatDrug Text^Numbe rOfDoses ,,
  2   ACETAMINOP HEN 325MG  TAB^ACETAM INOPHEN-N  TAB^^^N^N^ N^N^N^N^N^ N^N^N^N^N^ FORMULARY^ EA-EACH^1^ ^N^^^0-NO  PRODUCT SE LECTION IN DICATED^^^ ^^^^0^0^^^ ^^N^N^^^^^ 1^^^^^^^^^ ^^^^^^^0-U nscheduled ^^DT5^ ,,
  3   DIGOXIN 0. 25MG TAB^D IGOXIN TAB ^^^N^N^N^N ^N^N^N^N^N ^N^N^N^FOR MULARY^EA- EACH^1^^N^ ^^0-NO PRO DUCT SELEC TION INDIC ATED^^^^^^ ^0^0^^^^^N ^N^^^^^1^^ ^^^^^^^^^^ ^^^^0-Unsc heduled^^D T5^ ,,
  4   LISINOPRIL  10MG TAB^ LISINOPRIL  TAB^^^N^N ^N^N^N^N^N ^N^N^N^N^N ^FORMULARY ^EA-EACH^1 ^^N^^^0-NO  PRODUCT S ELECTION I NDICATED^^ ^^^^^0^0^^ ^^^N^N^^^^ ^1^^^^^^^^ ^^^^^^^^0- Unschedule d^^DT5^ ,,
  5   LISINOPRIL  40MG TAB^ LISINO-N T AB^^^N^N^N ^N^N^N^N^N ^N^N^N^N^F ORMULARY^E A-EACH^1^^ N^^^0-NO P RODUCT SEL ECTION IND ICATED^^^^ ^^^0^0^^^^ ^N^N^^^^^1 ^^^^^^^^^^ ^^^^^^0-Un scheduled^ ^DT5^ ,,
  6   PSEUDOEPHE DRINE HCL  60MG TAB^P SEUDOEPHED RINE-N HCL  TAB^^^N^N ^N^N^N^N^N ^N^N^N^N^N ^FORMULARY ^EA-EACH^1 ^^N^^^0-NO  PRODUCT S ELECTION I NDICATED^^ ^^^^^0^0^^ ^^^N^N^^^^ ^1^^^^^^^^ ^^^^^^^^0- Unschedule d^^DT5^ ,,
  7   SIMVASTATI N 40MG TAB ^SIMVASTAT IN TAB^^^N ^N^N^N^N^N ^N^N^N^N^N ^N^FORMULA RY^EA-EACH ^1^^N^^^0- NO PRODUCT  SELECTION  INDICATED ^^^^^^^0^0 ^^^^^N^N^^ ^^^1^^^^^^ ^^^^^^^^^^ 0-Unschedu led^^DT5^ ,,
  8   ATOMOXETIN E 60MG CAP ^ATOMOXETI NE CAP^^^N ^N^N^N^N^N ^N^N^N^N^N ^N^FORMULA RY^EA-EACH ^1^^N^^^0- NO PRODUCT  SELECTION  INDICATED ^^^^^^^0^0 ^^^^^N^N^^ ^^^1^^^^^^ ^^^^^^^^^^ 0-Unschedu led^^DT5^ ,,
  9   TEMAZEPAM  15MG CAP,O RAL^TEMAZE PAM CAP^^^ N^N^N^N^N^ N^N^N^N^N^ N^N^FORMUL ARY^EA-EAC H^1^^N^^^0 -NO PRODUC T SELECTIO N INDICATE D^^^^^^^0^ 0^^^^^N^N^ ^^^^1^^^^^ ^^^^^^^^^^ ^0-Unsched uled^^DT5^ ,
  10   OXYMORPHON E HCL 10MG  TAB^OXYMO RPHONE HCL  TAB^^^N^N ^N^N^N^N^N ^N^N^N^N^N ^FORMULARY ^EA-EACH^1 ^^N^^^0-NO  PRODUCT S ELECTION I NDICATED^^ ^^^^^0^0^^ ^^^N^N^^^^ ^1^^^^^^^^ ^^^^^^^^0- Unschedule d^^DT5^ ,,
  11   RISPERIDON E 2MG TAB, ORAL DISIN TEGRATING^ RISPERIDON E TAB,ORAL  DISINTEGR ATING^^^N^ N^N^N^N^N^ N^N^N^N^N^ N^FORMULAR Y^EA-EACH^ 1^^N^^^0-N O PRODUCT  SELECTION  INDICATED^ ^^^^^^0^0^ ^^^^N^N^^^ ^^1^^^^^^^ ^^^^^^^^^0 -Unschedul ed^^DT5^
  12   ACARBOSE 1 00MG TAB^A CARBOSE TA B^^PRECOSE ::00026-28 62-51::::: :0-TRADE N AME::BT::4 8.63::100. 0::0.49^N^ N^N^N^N^N^ N^N^N^N^N^ N^FORMULAR Y^EA-EACH^ 1^^N^^^0-N O PRODUCT  SELECTION  INDICATED^ ^^^^^^0^0^ ^^^^N^N^^^ ^^0^^^^^^^ ^^^^^^^^^0 -Unschedul ed^^^ ,,
  13   AMOXICILLI N TRIHYDRA TE 500MG/C LAVULANATE  K 125MG T AB^AMOXICI LLIN/CLAVU LANATE TAB ^^^N^N^N^N ^N^N^N^N^N ^N^N^N^FOR MULARY^EA- EACH^1^^N^ ^^0-NO PRO DUCT SELEC TION INDIC ATED^^^^^^ ^0^0^^^^^N ^N^^^^^0^^ ^^^^^^^^^^ ^^^^0-Unsc heduled^^^ ,,
  14   ATROPINE S O4 1% OINT ,OPH^ATROP INE OINT,O PH^^000000 2185117::0 000002-185 1-17:::::: D-DRUG ACC OUNTABILIT Y::TU::0.9 4::1.0::0. 94||ISOPTO  ATROPINE: :0000002-1 851-17:::: ::0-TRADE  NAME::TU:: 0.94::1.0: :0.94^N^N^ N^N^N^N^N^ N^N^N^N^N^ FORMULARY^ EA-EACH^1^ ^N^^^0-NO  PRODUCT SE LECTION IN DICATED^^^ ^^^^0^0^^^ ^^N^N^^^^^ 0^^^^^^^^^ ^^^^^^^0-U nscheduled ^^^
  15   CELECOXIB  200MG CAP^ CELECOXIB  CAP,ORAL^^ ^N^N^N^N^N ^N^N^N^N^N ^N^N^FORMU LARY^EA-EA CH^1^^N^^^ 0-NO PRODU CT SELECTI ON INDICAT ED^^^^^^^0 ^0^^^^^N^N ^^^^^0^^^^ ^^^^^^^^^^ ^^0-Unsche duled^^^ ,
  16   CEPHALEXIN  250MG/5ML  SUSP^CEPH ALEXIN PWD R,RENST-OR AL^^^N^N^N ^N^N^N^N^N ^N^N^N^N^F ORMULARY^E A-EACH^1^^ N^^^0-NO P RODUCT SEL ECTION IND ICATED^^^^ ^^^0^0^^^^ ^N^N^^^^^0 ^^^^^^^^^^ ^^^^^^0-Un scheduled^ ^^ ,
  17   CLONIDINE  0.3MG/24HR S PATCH^CL ONIDINE PA TCH^^^N^N^ N^N^N^N^N^ N^N^N^N^N^ FORMULARY^ EA-EACH^1^ ^N^^^0-NO  PRODUCT SE LECTION IN DICATED^^^ ^^^^0^0^^^ ^^N^N^^^^^ 0^^^^^^^^^ ^^^^^^^0-U nscheduled ^^^ ,,
  18   IBUPROFEN  400MG TAB^ IBUPROFEN  TAB^^IBUPR OFEN 400MG  TAB::5374 6-0131-05: :::::0-TRA DE NAME::B T::5.6::50 0.0::0.01^ N^N^N^N^N^ N^N^N^N^N^ N^N^FORMUL ARY^EA-EAC H^1^^N^^^0 -NO PRODUC T SELECTIO N INDICATE D^^^^^^^0^ 0^^^^^N^N^ ^^^^0^^^^^ ^^^^^^^^^^ ^0-Unsched uled^^^ ,,
  19   LITHIUM CA RBONATE 30 0MG TAB,SA ^LITHIUM T AB,SA^^^N^ N^N^N^N^N^ N^N^N^N^N^ N^FORMULAR Y^EA-EACH^ 1^^N^^^0-N O PRODUCT  SELECTION  INDICATED^ ^^^^^^0^0^ ^^^^N^N^^^ ^^0^^^^^^^ ^^^^^^^^^0 -Unschedul ed^^^
  20   LINDANE 1%  SHAMPOO^L INDANE SHA MPOO^^0172 36077116:: 017236-077 1-16:::::: D-DRUG ACC OUNTABILIT Y::BT::59. 26::60.0:: 0.99||BENZ ENE HEXACH LORIDE SHA MPOO::0021 -0610-16:: ::::0-TRAD E NAME::BT ::59.26::6 0.0::0.99| |KWELL SHA MPOO::0021 -0610-16:: ::::0-TRAD E NAME::BT ::59.26::6 0.0::0.99| |GAMMA BEN ZENE::0021 -0610-16:: ::::0-TRAD E NAME::BT ::59.26::6 0.0::0.99| |KWELL::00 21-0610-16 ::::::0-TR ADE NAME:: BT::59.26: :60.0::0.9 9^N^N^N^N^ N^N^N^N^N^ N^N^N^FORM ULARY^EA-E ACH^1^^N^^ ^0-NO PROD UCT SELECT ION INDICA TED^^^^^^^ 0^0^^^^^N^ N^^^^^0^^^ ^^^^^^^^^^ ^^^0-Unsch eduled^^^ ,,
  21   LORAZEPAM  1MG TAB^LO RAZEPAM TA B^^ATIVAN  1MG::0008- 0064-02::: :::0-TRADE  NAME::BT: :9.45::100 .0::0.1||0 0000800640 2::0008-00 64-02::::: :D-DRUG AC COUNTABILI TY::BT::9. 45::100.0: :0.1||ATIV AN::0008-0 064-02:::: ::0-TRADE  NAME::BT:: 9.45::100. 0::0.1^N^N ^N^N^N^N^N ^N^N^N^N^N ^FORMULARY ^EA-EACH^1 ^^N^^^0-NO  PRODUCT S ELECTION I NDICATED^^ ^^^^^0^0^^ ^^^N^N^^^^ ^0^^^^^^^^ ^^^^^^^^0- Unschedule d^^^ ,,
  22   WARFARIN N A 7.5MG TA B^WARFARIN  TAB^^WARF ARIN (COUM ADIN) NA 7 .5MG TAB:: 00056-0173 -70::::::1 -QUICK COD E::BT::19. 27::100.0: :0.19||COU MADIN::000 56-0173-70 ::::::1-QU ICK CODE:: BT::19.27: :100.0::0. 19^N^N^N^N ^N^N^N^N^N ^N^N^N^FOR MULARY^EA- EACH^1^^N^ ^^0-NO PRO DUCT SELEC TION INDIC ATED^^^^^^ ^0^0^^^^^N ^N^^^^^0^^ ^^^^^^^^^^ ^^^^0-Unsc heduled^^^ ,,
  23   ACETAMINOP HEN 523MG  TAB^OPIUM  TAB^201109 12^Name2:: 12345-9999 -45::Vendo r2::VSN2:: 1-QUICK CO DE::PT::17 .01::17.02 ::17.03||N ame1::1234 5-9999-44: :Vendor1:: VSN1::D-DR UG ACCOUNT ABILITY::B X::11.11:: 22.22::33. 33^Y^Y^Y^Y ^Y^Y^Y^Y^Y ^Y^Y^Y^FOR MULARY WIT H RESTRICT IONS^ML-MI LLILITERS^ 12^Y^Y^3-B LOOD PRODU CT^6000^7- SUBSTITUTI ON NOT ALL OWED-BRAND  DRUG MAND ATED BY LA W^45D^255^ There is a  high limi t for this  order^The re is a lo w limit fo r this sch edule^You  should ove rride this ^This is t he overrid e^800^85^Q uantity Ov erride is  entered^Th e reason f or the ove rride^222. 3344^FSN10 0/NSN200^Y ^Y^EVERY 1 6 Minutes^ 400 Days^2 0 Minutes^ 372.90879^ 25^This is  the Rx--M essage^899 ^BX^Todd S chippers^D ispense Th is Quantit y^INAPPROP RIATE_REQU EST^Reject  this item ^LINCOMYCI NS::AM350| |INVESTIGA TIONAL GEN E THERAPY: :IN950^Tot al Dispens y Quantity ^3 Hours^P  - PRN^Y^F ederal Exp ress^2-CLA SS 2^tallm anLETTERin g^6-Legend  Item^RN37 B^DT1||DT4 ^172 ,,